Regeneron Inks $3 Billion Fujifilm Deal to Bolster US Drugmaking
Regeneron Pharmaceuticals Inc. agreed to pay Fujifilm Diosynth Biotechnologies more than $3 billion over the next decade to help manufacture its medicines in the US, as the threat of tariffs looms over the nation's drug supply.
Fujifilm will produce drugs for Regeneron, maker of the $14 billion a year inflammation treatment Dupixent, at its facility in Holly Springs, North Carolina. The site is slated to begin operations later this year and future expansions are already being planned, Fujifilm said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 hours ago
- Yahoo
Regeneron Pharmaceuticals, Inc. (REGN): A Bull Case Theory
We came across a bullish thesis on Regeneron Pharmaceuticals, Inc. (REGN) on Notes From The Beauty Contest's Substack. In this article, we will summarize the bulls' thesis on REGN. Regeneron Pharmaceuticals, Inc. (REGN)'s share was trading at $605.39 as of 29th May. REGN's trailing and forward P/E were 15.39 and 17.39 respectively according to Yahoo Finance. A scientist in a lab conducting research on cell-based therapeutics and biotechnology. Regeneron's latest earnings report was notably weak, with a 3.7% revenue decline and a 14% EPS drop, surprising given the company's history of exceeding market expectations. The primary driver was a steep 26% year-over-year decline in the U.S. Eylea franchise, particularly a 39% drop in 2mg Eylea sales. This was partly due to a co-pay assistance funding gap, which forced many Medicare patients to switch to cheaper alternatives like compounded Avastin, impacting both Regeneron and rival Roche's Vabysmo. Regeneron, having contributed over $400 million last year to charitable foundations supporting co-pay assistance, is now seeking to share this burden, proposing a matching donation program to encourage broader industry support. Another setback was the FDA's Complete Response Letter delaying approval of the Eylea-HD pre-filled syringe, a key product needed to compete with Vabysmo. The delay stemmed from third-party component issues rather than drug efficacy, and management believes resolution could be near. Margins also contracted, with gross margin falling from 89% to 85% due to unspecified inventory write-offs, possibly related to older Eylea 2mg or even leftover REGEN-COV stock. However, the margin pressure appears more tied to one-offs and increased R&D spending than structural issues. On a more positive note, Regeneron's pipeline is broadening meaningfully. Itepekimab, an IL-33 antibody, shows promise as a major respiratory asset with pivotal COPD data upcoming and expanded trials underway. The growing RNAi pipeline, now at nine siRNAs through its Alnylam collaboration, signals Regeneron's potential evolution beyond antibodies into a broader genetic medicine powerhouse. Regeneron Pharmaceuticals, Inc. (REGN) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 66 hedge fund portfolios held REGN at the end of the first quarter which was 68 in the previous quarter. While we acknowledge the potential of LYFT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey. Sign in to access your portfolio
Forbes
a day ago
- Forbes
Agfa Launches Three New Digital Photo Products All Ready For A Summer Of Fun
The new Agfa Realkids Cam Waterproof 2 is designed for kids and can shoot stills and videos. For more than a century, the photographic market has been dominated by three big brands. First came Kodak, the granddaddy of them all, founded in Rochester, New York, in 1892. Its yellow, black and red branding is still one of the most recognizable in the world. However, strong competition from Japan's Fujifilm, a relative upstart founded in 1934, put pressure on Kodak in the late 1990s pushing it to the brink of bankruptcy in 2011. Today the brand goes on but the brand is often licensed to third parties producing photographic products for the digital age. The third dominant force in photography was Agfa-Gevaert, a Belgian German company founded in 1867 as a dye manufacturer. The company endured a chequered history, especially during World War II. Like Kodak today, the name is often licensed to several businesses producing digital photography products that want to leverage such a well-known brand. Now the Agfa name is back in the photography business with a trio of fun, new products that could keep the kids happy during the long summer holidays. The first is the new Realkids Cam Waterproof 2. The Realkids Cam Waterproof 2 from Agfa has a 2.8-inch color display and speaker. FEATURED | Frase ByForbes™ Unscramble The Anagram To Reveal The Phrase Pinpoint By Linkedin Guess The Category Queens By Linkedin Crown Each Region Crossclimb By Linkedin Unlock A Trivia Ladder While it's hardly the snappiest name, there's no doubt what it is and what it does. The little waterproof camera has a colorful and child-friendly design and takes HD photos and videos. It has two lenses and includes a 2.8-inch color display for lining up the shots. The Agfa Realkids Cam Waterproof 2 can resist a plunge in the water down to 3 meters or 10 feet; we're talking paddling pool duty here rather than scuba diving. The camera is powered by a 1,200mAh rechargeable lithium battery and provides resolutions up to 12 megapixels with videos topping out at 1080p/2.7k. The camera has a slot for a 128GB microSD card and records images as JPEGs and movies as MOV. There is a selfie mode and a selection of built-in digital filters for adding a little personality to the shots. There are also some games onboard for long car journeys and a speaker for the sound effects. The Agfa Realmove MC3X is a mini gimbal camera for making videos on the move. The next new product to bear the brand is the Agfa Realmove MC3X, a mini gimbal camera for making videos on the move. The MC3X shoots in 4K resolution and has 3-axis stabilization for smooth and handheld shooting. This pocket-sized camera and gimbal delivers pro-quality footage and is suitable for shooting scenic landscapes or action. As well as shooting videos, the camera can also take still images with resolutions of up to 20 megapixels in JPEG format. The lens has a wide 120-degree view and includes Wi-Fi support. All videos and images recorded by the MC3X are stored on a microSD card. The camera's memory card slot can take cards up to 512GB. The 1,450mAh rechargeable lithium battery can last for 170 minutes of continuous shooting. Other features include a mini-HDMI output and a 3.5mm microphone input. The Agfa Realipix Mini P.2 portable photo printer is battery-powered and prints high-quality color ... More photos without the need for ink. The final product of the trio is the Agfa Realipix Mini P.2 portable photo printer. The battery-powered gadget and print high-quality color photos without the need for ink. It has a Bluetooth connection and is compatible with iOS and Android devices. Using Zink printing technology, the Realipix Mini P.2 portable photo printer produces 5 x 7.6cm or 2 x 3-inch color photos. Weighing just 189g, the lightweight printer includes digital filters and editing functions for embellishing images. The Agfa Realkids Cam Waterproof 2 is available now and costs £58.37 / €69,99. The Agfa Realmove MC3X mini gimbal camera is also available now and priced at £291.86 / €349,99. Finally, the Agfa Realipix Mini P.2 portable photo printer is shipping now and costs £52.53 / €62,99.
Business Insider
a day ago
- Business Insider
Sanofi (SNY) Takes Bold $9.5Bn Immunology Leap
Sanofi (SNY) has its hands full—in the best way possible—after announcing its $9.5 billion acquisition of Blueprint Medicines. This marks the French pharma giant's fourth major strategic acquisition this year, but this deal stands out. Sanofi isn't just picking up a drug or two; it's gaining access to a robust immunology pipeline of internally developed therapies. In addition to securing Ayvakit, a treatment for systemic mastocytosis, the acquisition reinforces Sanofi's shift toward high-value biopharma assets. Despite recent stock underperformance, this bold move strengthens my long-term bullish outlook on Sanofi. Confident Investing Starts Here: Sanofi's Strategic Pivot Towards High-Value Biopharma Sanofi's recent sale of Opella, its consumer healthcare division, highlights a broader strategic shift toward prioritizing high-margin biopharma operations. The company has seen major success with Dupixent—a blockbuster drug for inflammatory conditions like COPD and dermatitis, which generated over $13 billion in sales last year and now makes up nearly 30% of Sanofi's total revenue. This move underscores Sanofi's commitment to doubling down on its most profitable and innovative drug assets. Immediate Ayvakit Revenue Sanofi's acquisition of Blueprint, while a sizable investment, brings immediate benefits in both revenue diversification and pipeline strength. Ayvakit, approved for treating advanced systemic mastocytosis (AdvSM) in 2021 and indolent systemic mastocytosis (ISM) in 2023, addresses a rare disease with few treatment options. The drug generated $479 million in 2024, and Blueprint projected up to $720 million in revenue for 2025. With peak annual sales expected to reach around $2 billion before 2030, Ayvakit offers Sanofi a strong, near-term revenue driver, helping to de-risk the $9.1 billion upfront cost. Strategically, it's also a seamless addition to Sanofi's growing immunology portfolio. Boosting Sanofi's Immunology Future with Blueprint's Pipeline While Blueprint's pipeline includes several candidates, the spotlight is on two key assets: elenestinib and BLU-808. Elenestinib is a next-generation KIT D816V inhibitor currently in late-stage development for systemic mastocytosis (SM). It aims to improve upon the safety profile of Ayvakit, potentially appealing to patients who may avoid Ayvakit due to side effects such as fatigue and cognitive impairment, thereby expanding Sanofi's market share in SM. BLU-808, on the other hand, is an early-stage asset targeting a broader range of inflammatory conditions, including allergic asthma and allergic rhinoconjunctivitis. Unlike SM, these are far more prevalent diseases, offering significantly larger commercial opportunities. Importantly, BLU-808 is tied to two contingent value rights (CVRs), which are dependent on achieving specific development and regulatory milestones. These CVRs provide a layer of downside protection for Sanofi—if BLU-808 fails in clinical trials, the company's overall payout for the asset is reduced. Navigating Margin Pressures with Strategic Investment All of this comes against the backdrop of ongoing margin pressures for Sanofi. The company has already walked back its 2025 operating margin target of 32%, citing pricing pressures in its legacy general medicines segment and a ramp-up in R&D spending. While Sanofi remains active in diabetes with drugs like Lantus and Toujeo, these products now face significant pricing headwinds from generics, making them far less profitable than they once were. The Blueprint acquisition underscores Sanofi's renewed focus on innovation and high-margin biopharma assets. Though this pivot comes at the cost of near-term margin dilution, it reflects a longer-term strategy: investing in R&D today in hopes of developing the next wave of blockbuster therapies. In this context, Sanofi is clearly still in the midst of a strategic transformation—one currently anchored by the strong performance of Dupixent. Unlike previous 'bolt-on' deals that added just a drug or two, the Blueprint acquisition marks a more decisive step toward reshaping Sanofi's portfolio around premium, next-generation therapeutics. What is the Price Prediction for SNY Stock? On Wall Street, SNY sports a consensus Moderate Buy rating based on two Buy, three Hold, and zero Sell ratings in the past three months. Sanofi's average stock price target of $62.20 implies ~25% upside potential over the next 12 months. Last week, analyst Sachin Jain from Bank of America Securities maintained a Buy rating on SNY. The analyst was bullish on Sanofi's pipeline, particularly itepekimab, despite it failing in one of two Phase 3 trials for COPD. Moreover, he noted that 'Sanofi's low price-to-earnings ratio, reflecting limited pipeline upside, is seen as an opportunity given the promising data from these trials, indicating a potential R&D turnaround for the company.' Blueprint Deal Seals the Verdict on SNY In summary, Sanofi's acquisition of Blueprint offers both near-term revenue and long-term growth potential. Ayvakit serves as a valuable bolt-on asset, while pipeline candidates like elenestinib and BLU-808 significantly enhance Sanofi's immunology portfolio. More importantly, the deal reflects Sanofi's strategic pivot toward higher-margin biopharma assets at a time when older drugs like Lantus are facing profitability headwinds. Though the investment may pressure margins in the short run, it sets the stage for long-term growth in a high-value segment of the pharmaceutical market. Notably, the deal is expected to be EPS accretive by 2027, thanks to Ayvakit's revenue potential, which will help justify and offset a large portion of the upfront $9.5 billion cost. Overall, Sanofi has secured a promising set of assets at a reasonable valuation while extending its leadership in immunology beyond Dupixent. With a modest P/E ratio of 20.5 and a solid 3.27% dividend yield, SNY stands out as a compelling long-term investment opportunity for investors seeking to tap into the expanding biopharmaceutical space.
